Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

Takashi Ishige; Toshiaki Shimizu; Kenji Watanabe; Katsuhiro Arai; Koichi Kamei; Takahiro Kudo; Reiko Kunisaki; Daisuke Tokuhara; Makoto Naganuma; Tatsuki Mizuochi; Atsuko Murashima; Yuta Inoki; Naomi Iwata; Itaru Iwama; Sachi Koinuma; Hirotaka Shimizu; Keisuke Jimbo; Yugo Takaki; Shohei Takahashi; Yuki Cho; Ryusuke Nambu; Daisuke Nishida; Shin ichiro Hagiwara; Norikatsu Hikita; Hiroki Fujikawa; Kenji Hosoi; Shuhei Hosomi; Yohei Mikami; Jun Miyoshi; Ryusuke Yagi; Yoko Yokoyama; Tadakazu Hisamatsu

doi:10.1007/s00535-022-01953-w

Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

Takashi Ishige, Toshiaki Shimizu, Kenji Watanabe, Katsuhiro Arai, Koichi Kamei, Takahiro Kudo, Reiko Kunisaki, Daisuke Tokuhara, Makoto Naganuma, Tatsuki Mizuochi, Atsuko Murashima, Yuta Inoki, Naomi Iwata, Itaru Iwama, Sachi Koinuma, Hirotaka Shimizu, Keisuke Jimbo, Yugo Takaki, Shohei Takahashi, Yuki ChoRyusuke Nambu, Daisuke Nishida, Shin ichiro Hagiwara, Norikatsu Hikita, Hiroki Fujikawa, Kenji Hosoi, Shuhei Hosomi, Yohei Mikami, Jun Miyoshi, Ryusuke Yagi, Yoko Yokoyama, Tadakazu Hisamatsu

Department of Internal Medicine (Gastroenterology and Hepatology)

Research output: Contribution to journal › Article › peer-review

Abstract

Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation of IBD treatment because patients with IBD frequently undergo continuous treatment with immunosuppressive drugs. This consensus was developed to support the decision-making process regarding appropriate vaccination for pediatric and adult patients with IBD and physicians by providing critical information according to the published literature and expert consensus about vaccine-preventable diseases (VPDs) [excluding cervical cancer and coronavirus disease 2019 (COVID-19)] in Japan. This consensus includes 19 important clinical questions (CQs) on the following 4 topics: VPDs (6 CQs), live attenuated vaccines (2 CQs), inactivated vaccines (6 CQs), and vaccination for pregnancy, childbirth, and breastfeeding (5 CQs). These topics and CQs were selected under unified consensus by the members of a committee on intractable diseases with support by a Health and Labour Sciences Research Grant. Physicians should provide necessary information on VPDs to their patients with IBD and carefully manage these patients’ IBD if various risk factors for the development or worsening of VPDs are present. This consensus will facilitate informed and shared decision-making in daily IBD clinical practice.

Original language	English
Pages (from-to)	135-157
Number of pages	23
Journal	Journal of gastroenterology
Volume	58
Issue number	2
DOIs	https://doi.org/10.1007/s00535-022-01953-w
Publication status	Published - 2023 Feb

Keywords

Crohn’s disease
Immunization
Ulcerative colitis
Vaccine-preventable disease

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00535-022-01953-w

Cite this

Ishige, T., Shimizu, T., Watanabe, K., Arai, K., Kamei, K., Kudo, T., Kunisaki, R., Tokuhara, D., Naganuma, M., Mizuochi, T., Murashima, A., Inoki, Y., Iwata, N., Iwama, I., Koinuma, S., Shimizu, H., Jimbo, K., Takaki, Y., Takahashi, S., ... Hisamatsu, T. (2023). Expert consensus on vaccination in patients with inflammatory bowel disease in Japan. Journal of gastroenterology, 58(2), 135-157. https://doi.org/10.1007/s00535-022-01953-w

Ishige, T, Shimizu, T, Watanabe, K, Arai, K, Kamei, K, Kudo, T, Kunisaki, R, Tokuhara, D, Naganuma, M, Mizuochi, T, Murashima, A, Inoki, Y, Iwata, N, Iwama, I, Koinuma, S, Shimizu, H, Jimbo, K, Takaki, Y, Takahashi, S, Cho, Y, Nambu, R, Nishida, D, Hagiwara, SI, Hikita, N, Fujikawa, H, Hosoi, K, Hosomi, S, Mikami, Y, Miyoshi, J, Yagi, R, Yokoyama, Y & Hisamatsu, T 2023, 'Expert consensus on vaccination in patients with inflammatory bowel disease in Japan', Journal of gastroenterology, vol. 58, no. 2, pp. 135-157. https://doi.org/10.1007/s00535-022-01953-w

@article{9f91bdeb4abf4ef4a95c184e37b70d46,

title = "Expert consensus on vaccination in patients with inflammatory bowel disease in Japan",

abstract = "Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation of IBD treatment because patients with IBD frequently undergo continuous treatment with immunosuppressive drugs. This consensus was developed to support the decision-making process regarding appropriate vaccination for pediatric and adult patients with IBD and physicians by providing critical information according to the published literature and expert consensus about vaccine-preventable diseases (VPDs) [excluding cervical cancer and coronavirus disease 2019 (COVID-19)] in Japan. This consensus includes 19 important clinical questions (CQs) on the following 4 topics: VPDs (6 CQs), live attenuated vaccines (2 CQs), inactivated vaccines (6 CQs), and vaccination for pregnancy, childbirth, and breastfeeding (5 CQs). These topics and CQs were selected under unified consensus by the members of a committee on intractable diseases with support by a Health and Labour Sciences Research Grant. Physicians should provide necessary information on VPDs to their patients with IBD and carefully manage these patients{\textquoteright} IBD if various risk factors for the development or worsening of VPDs are present. This consensus will facilitate informed and shared decision-making in daily IBD clinical practice.",

keywords = "Crohn{\textquoteright}s disease, Immunization, Ulcerative colitis, Vaccine-preventable disease",

author = "Takashi Ishige and Toshiaki Shimizu and Kenji Watanabe and Katsuhiro Arai and Koichi Kamei and Takahiro Kudo and Reiko Kunisaki and Daisuke Tokuhara and Makoto Naganuma and Tatsuki Mizuochi and Atsuko Murashima and Yuta Inoki and Naomi Iwata and Itaru Iwama and Sachi Koinuma and Hirotaka Shimizu and Keisuke Jimbo and Yugo Takaki and Shohei Takahashi and Yuki Cho and Ryusuke Nambu and Daisuke Nishida and Hagiwara, {Shin ichiro} and Norikatsu Hikita and Hiroki Fujikawa and Kenji Hosoi and Shuhei Hosomi and Yohei Mikami and Jun Miyoshi and Ryusuke Yagi and Yoko Yokoyama and Tadakazu Hisamatsu",

note = "Funding Information: This work was supported in part by a Health and Labour Sciences Research Grant for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (Hisamatsu 20316729). The authors thank Angela Morben, DVM, ELS, from Edanz ( https://jp.edanz.com/ac ), for editing a draft of this manuscript. Publisher Copyright: {\textcopyright} 2023, Japanese Society of Gastroenterology.",

year = "2023",

month = feb,

doi = "10.1007/s00535-022-01953-w",

language = "English",

volume = "58",

pages = "135--157",

journal = "Journal of Gastroenterology",

issn = "0944-1174",

publisher = "Springer Japan",

number = "2",

}

TY - JOUR

T1 - Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

AU - Ishige, Takashi

AU - Shimizu, Toshiaki

AU - Watanabe, Kenji

AU - Arai, Katsuhiro

AU - Kamei, Koichi

AU - Kudo, Takahiro

AU - Kunisaki, Reiko

AU - Tokuhara, Daisuke

AU - Naganuma, Makoto

AU - Mizuochi, Tatsuki

AU - Murashima, Atsuko

AU - Inoki, Yuta

AU - Iwata, Naomi

AU - Iwama, Itaru

AU - Koinuma, Sachi

AU - Shimizu, Hirotaka

AU - Jimbo, Keisuke

AU - Takaki, Yugo

AU - Takahashi, Shohei

AU - Cho, Yuki

AU - Nambu, Ryusuke

AU - Nishida, Daisuke

AU - Hagiwara, Shin ichiro

AU - Hikita, Norikatsu

AU - Fujikawa, Hiroki

AU - Hosoi, Kenji

AU - Hosomi, Shuhei

AU - Mikami, Yohei

AU - Miyoshi, Jun

AU - Yagi, Ryusuke

AU - Yokoyama, Yoko

AU - Hisamatsu, Tadakazu

N1 - Funding Information: This work was supported in part by a Health and Labour Sciences Research Grant for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (Hisamatsu 20316729). The authors thank Angela Morben, DVM, ELS, from Edanz ( https://jp.edanz.com/ac ), for editing a draft of this manuscript. Publisher Copyright: © 2023, Japanese Society of Gastroenterology.

PY - 2023/2

Y1 - 2023/2

N2 - Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation of IBD treatment because patients with IBD frequently undergo continuous treatment with immunosuppressive drugs. This consensus was developed to support the decision-making process regarding appropriate vaccination for pediatric and adult patients with IBD and physicians by providing critical information according to the published literature and expert consensus about vaccine-preventable diseases (VPDs) [excluding cervical cancer and coronavirus disease 2019 (COVID-19)] in Japan. This consensus includes 19 important clinical questions (CQs) on the following 4 topics: VPDs (6 CQs), live attenuated vaccines (2 CQs), inactivated vaccines (6 CQs), and vaccination for pregnancy, childbirth, and breastfeeding (5 CQs). These topics and CQs were selected under unified consensus by the members of a committee on intractable diseases with support by a Health and Labour Sciences Research Grant. Physicians should provide necessary information on VPDs to their patients with IBD and carefully manage these patients’ IBD if various risk factors for the development or worsening of VPDs are present. This consensus will facilitate informed and shared decision-making in daily IBD clinical practice.

AB - Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation of IBD treatment because patients with IBD frequently undergo continuous treatment with immunosuppressive drugs. This consensus was developed to support the decision-making process regarding appropriate vaccination for pediatric and adult patients with IBD and physicians by providing critical information according to the published literature and expert consensus about vaccine-preventable diseases (VPDs) [excluding cervical cancer and coronavirus disease 2019 (COVID-19)] in Japan. This consensus includes 19 important clinical questions (CQs) on the following 4 topics: VPDs (6 CQs), live attenuated vaccines (2 CQs), inactivated vaccines (6 CQs), and vaccination for pregnancy, childbirth, and breastfeeding (5 CQs). These topics and CQs were selected under unified consensus by the members of a committee on intractable diseases with support by a Health and Labour Sciences Research Grant. Physicians should provide necessary information on VPDs to their patients with IBD and carefully manage these patients’ IBD if various risk factors for the development or worsening of VPDs are present. This consensus will facilitate informed and shared decision-making in daily IBD clinical practice.

KW - Crohn’s disease

KW - Immunization

KW - Ulcerative colitis

KW - Vaccine-preventable disease

UR - http://www.scopus.com/inward/record.url?scp=85146330747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146330747&partnerID=8YFLogxK

U2 - 10.1007/s00535-022-01953-w

DO - 10.1007/s00535-022-01953-w

M3 - Article

C2 - 36629948

AN - SCOPUS:85146330747

SN - 0944-1174

VL - 58

SP - 135

EP - 157

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

IS - 2

ER -

Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this